Poly-ADP-ribosylation-mediated degradation of ARTD1 by the NLRP3 inflammasome is a prerequisite for osteoclast maturation

Cell Death and Disease

Volumn 7, Issue 3, 2016, Pages

  Wang, C ^a   Qu, C ^a   Alippe, Y ^a   Bonar, S L ^a   Civitelli, R ^a   Abu Amer, Y ^a   Hottiger, M O ^b   Mbalaviele, G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ADP RIBOSYLTRANSFERASE DIPHTHERIA TOXIN LIKE 1; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CATHEPSIN K; COLONY STIMULATING FACTOR 1; CRYOPYRIN; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR MAFB; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG; CARRIER PROTEIN; HISTONE; INFLAMMASOME; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NLRP3 PROTEIN, MOUSE; PARP1 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; BONE DENSITY; BONE MASS; CELL DIFFERENTIATION; CELL MATURATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EPIGENETICS; GENE EXPRESSION; HISTONE MODIFICATION; IMMUNOPRECIPITATION; IN VITRO STUDY; MACROPHAGE; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PHENOTYPE; POLY(ADENOSINE DIPHOSPHATE) RIBOSYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; RAW 264.7 CELL LINE; REPRESSOR GENE; UPREGULATION; AMINO ACID SUBSTITUTION; ANIMAL; CYTOLOGY; GENETIC TRANSCRIPTION; GENETICS; KNOCKOUT MOUSE; METABOLISM; MISSENSE MUTATION; PROTEIN PROCESSING;

AMINO ACID SUBSTITUTION; ANIMALS; CARRIER PROTEINS; HISTONES; INFLAMMASOMES; MICE; MICE, KNOCKOUT; MUTATION, MISSENSE; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; OSTEOCLASTS; POLY (ADP-RIBOSE) POLYMERASE-1; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS; TRANSCRIPTION, GENETIC;

EID: 84979499463     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.58     Document Type: Article

References (49)

1. Novack DV, Teitelbaum SL. The Osteoclast: friend or foe? Annu Rev Pathol 2008; 3: 457–484.
2. Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol 2014; 6.
3. Otero K, Turnbull IR, Poliani PL, Vermi W, Cerutti E, Aoshi T et al. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and [beta]-catenin. Nat Immunol 2009; 10: 734–743.
4. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165–176.
5. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci 1998; 95: 3597–3602.
6. Lu S-Y, Li M, Lin Y-L. Mitf induction by RANKL Is critical for osteoclastogenesis. Mol Biol Cell 2010; 21: 1763–1771.
7. Abu-Amer Y. NF-κB signaling and bone resorption. Osteoporos Int 2013; 24: 2377–2386.
8. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994; 266: 443–448.
9. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3: 889–901.
10. Nishikawa K, Nakashima T, Hayashi M, Fukunaga T, Kato S, Kodama T et al. Blimp1-mediated repression of negative regulators is required for osteoclast differentiation. Proc Natl Acad Sci 2010; 107: 3117–3122.
11. Lee J, Kim K, Kim JH, Jin HM, Choi HK, Lee SH et al. Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. Blood 2006; 107: 2686–2693.
12. Kim K, Kim JH, Lee J, Jin HM, Kook H, Kim KK et al. MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood 2007; 109: 3253–3259.
13. Zhao B, Takami M, Yamada A, Wang X, Koga T, Hu X et al. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat Med 2009; 15: 1066–1071.
14. Kim JH, Youn BU, Kim K, Moon JB, Lee J, Nam KI et al. Lhx2 regulates bone remodeling in mice by modulating RANKL signaling in osteoclasts. Cell Death Differ 2014; 21: 1613–1621.
15. Alhawagri M, Yamanaka Y, Ballard D, Oltz E, Abu-Amer Y. Lysine392, a K63-linked ubiquitination site in NEMO, mediates inflammatory osteoclastogenesis and osteolysis. J Orthop Res 2012; 30: 554–560.
16. Bronisz A, Carey HA, Godlewski J, Sif S, Ostrowski MC, Sharma SM. The multifunctional protein fused in sarcoma (FUS) Is a coactivator of microphthalmia-associated transcription factor (MITF). J Biol Chem 2014; 289: 326–334.
17. Hottiger MO, Hassa PO, Lüscher B, Schüler H, Koch-Nolte F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci 2010; 35: 208–219.
18. Lupo B, Trusolino L. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. Biochim Biophys Acta 2014; 1846: 201–215.
19. Messner S, Hottiger MO. Histone ADP-ribosylation in DNA repair, replication and transcription. Trends Cell Biol 2011; 21: 534–542.
20. Fouquerel E, Sobol RW. ARTD1 (PARP1) activation and NAD+ in DNA repair and cell death. DNA Repair 2014; 23: 27–32.
21. Kraus WL, Hottiger MO. PARP-1 and gene regulation: progress and puzzles. Mol Aspects Med 2013; 34: 1109–1123.
22. Valdor R, Schreiber V, Saenz L, Martínez T, Muñoz-Suano A, Dominguez-Villar M et al. Regulation of NFAT by poly(ADP-ribose) polymerase activity in T cells. Mol Immunol 2008; 45: 1863–1871.
23. Olabisi OA, Soto-Nieves N, Nieves E, Yang TT, Yang X, Yu RY et al. Regulation of transcription factor NFAT by ADP-ribosylation. Mol Cell Biol 2008; 28: 2860–2871.
24. Kameoka M, Ota K, Tetsuka T, Tanaka Y, Itaya A, Okamoto T et al. Evidence for regulation of NF-kappaB by poly(ADP-ribose) polymerase. Biochem J 2000; 346: 641–649.
25. Petrilli V, Herceg Z, Hassa PO, Patel NS, Di Paola R, Cortes U et al. Noncleavable poly(ADP-ribose) polymerase-1 regulates the inflammation response in mice. J Clin Invest 2004; 114: 1072–1081.
26. Altmeyer M, Messner S, Hassa PO, Fey M, Hottiger MO. Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites. Nucleic Acids Res 2009; 37: 3723–3738.
27. Messner S, Schuermann D, Altmeyer M, Kassner I, Schmidt D, Schär P et al. Sumoylation of poly(ADP-ribose) polymerase 1 inhibits its acetylation and restrains transcriptional coactivator function. FASEB Journal 2009; 23: 3978–3989.
28. Kashima L, Idogawa M, Mita H, Shitashige M, Yamada T, Ogi K et al. CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation. J Biol Chem 2012; 287: 12975–12984.
29. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D et al. Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009; 183: 787–791.
30. Malireddi RK, Ippagunta S, Lamkanfi M, Kanneganti TD. Cutting edge: proteolytic inactivation of poly(ADP-ribose) polymerase 1 by the Nlrp3 and Nlrc4 inflammasomes. J Immunol 2010; 185: 3127–3130.
31. Beranger GE, Momier D, Rochet N, Quincey D, Guigonis JM, Samson M et al. RANKL treatment releases the negative regulation of the poly(ADP-Ribose) polymerase-1 on Tcirg1 gene expression during osteoclastogenesis. J Bone Miner Res 2006; 21: 1757–1769.
32. Beranger GE, Momier D, Rochet N, Carle GF, Scimeca J-C. Poly(adp-ribose) polymerase-1 regulates tracp gene promoter activity during RANKL-induced osteoclastogenesis. J Bone Miner Res 2008; 23: 564–571.
33. Chen J, Sun Y, Mao X, Liu Q, Wu H, Chen Y. RANKL up-regulates brain-type creatine kinase via poly(ADP-ribose) polymerase-1 during osteoclastogenesis. J Biol Chem 2010; 285: 36315–36321.
34. Takeshita S, Kaji K, Kudo A. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 2000; 15: 1477–1488.
35. Erener S, Pétrilli V, Kassner I, Minotti R, Castillo R, Santoro R et al. Inflammasome-activated caspase 7 cleaves PARP1 to enhance the expression of a subset of NF-κB target genes. Mol Cell 2012; 46: 200–211.
36. Jungmichel S, Rosenthal F, Altmeyer M, Lukas J, Hottiger MO, Nielsen ML. Proteome-wide identification of poly(ADP-Ribosyl)ation targets in different genotoxic stress responses. Mol Cell 2013; 52: 272–285.
37. Qu C, Bonar SL, Hickman-Brecks CL, Abu-Amer S, McGeough MD, Peña CA et al. NLRP3 mediates osteolysis through inflammation-dependent and-independent mechanisms. FASEB J 2015; 29: 1269–1279.
38. Robaszkiewicz A, Qu C, Wisnik E, Ploszaj T, Mirsaidi A, Kunze FA et al. ARTD1 regulates osteoclastogenesis and bone homeostasis by dampening NF-kB-dependent transcription of IL-1β. Sci Rep 2016; 6: 21131.
39. Tondravi MM, McKercher SR, Anderson K, Erdmann JM, Quiroz M, Maki R et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature 1997; 386: 81–84.
40. Desai S, Bolick SCE, Maurin M, Wright KL. PU.1 regulates positive regulatory domain I-binding factor 1/Blimp-1 transcription in lymphoma cells. J Immunol 2009; 183: 5778–5787.
41. Streppel MM, Pai S, Campbell NR, Hu C, Yabuuchi S, Canto MI et al. microRNA 223 Is Upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1. Clin Cancer Res 2013; 19: 4067–4078.
42. Andrabi SA, Umanah GK, Chang C, Stevens DA, Karuppagounder SS, Gagné JP et al. Poly (ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proc Natl Acad Sci 2014; 111: 10209–10214.
43. Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res 2000; 460: 1–15.
44. Bonar SL, Brydges SD, Mueller JL, McGeough MD, Pena C, Chen D et al. Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. PLoS ONE 2012; 7: e35979.
45. Scianaro R, Insalaco A, Bracci Laudiero L, De Vito R, Pezzullo M, Teti A et al. Deregulation of the IL-1β axis in chronic recurrent multifocal osteomyelitis. Pediatr Rheumatol 2014; 12: 1–6.
46. Youm Y-H, Grant RW, McCabe LR, Albarado DC, Nguyen KY, Ravussin A et al. Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab 2013; 18: 519–532.
47. Zhang Q, Yu W, Lee S, Xu Q, Naji A, Le AD. Bisphosphonate induces osteonecrosis of the jaw in diabetic mice via NLRP3/Caspase-1-dependent IL-1β mechanism. J Bone Miner Res 2015; 30: 2300–2312.
48. Burton L, Paget D, Binder NB, Bohnert K, Nestor BJ, Sculco TP et al. Orthopedic wear debris mediated inflammatory osteolysis is mediated in part by NALP3 inflammasome activation. J Orthop Res 2013; 31: 73–80.
49. Greenhill CJ, Jones GW, Nowell MA, Newton Z, Harvey AK, Moideen AN et al. Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. Arthritis Res Ther 2014; 16: 1–10.